|
1
|
Rajesh B, Zarranz-Ventura J, Fung AT,
Busch C, Sahoo NK, Rodriguez-Valdes PJ, Sarao V, Mishra SK, Saatci
AO, Udaondo Mirete P, et al: Safety of 6000 intravitreal
dexamethasone implants. Br J Ophthalmol. 104:39–46. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lowder C, Belfort R Jr, Lightman S, Foster
CS, Robinson MR, Schiffman RM, Li XY, Cui H and Whitcup SM: Ozurdex
HURON Study Group. Dexamethasone intravitreal implant for
noninfectious intermediate or posterior uveitis. Arch Ophthalmol.
129:545–553. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chang-Lin JE, Attar M, Acheampong AA,
Robinson MR, Whitcup SM, Kuppermann BD and Welty D:
Pharmacokinetics and pharmacodynamics of a sustained-release
dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci.
52:80–86. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Butt F and Devonport H: Treatment of
non-infectious posterior uveitis with dexamethasone intravitreal
implants in a real-world setting. Clin Ophthalmol. 17:601–611.
2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Karti O and Saatci AO: Intravitreal
dexamethasone implant in the treatment of non-infectious uveitic
macular edema. Med Hypothesis Discov Innov Ophthalmol. 7:169–175.
2018.PubMed/NCBI
|
|
6
|
Fan S, Shi XY, Zhao CF, Chen Z, Ying J, Yu
SP, Li J and Li X: Efficacy and safety of single-dose intravitreal
dexamethasone implant in non-infectious uveitic macular edema: A
systematic review and meta-analysis. Front Med (Lausanne).
10(1126724)2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jabs DA, Nussenblatt RB and Rosenbaum JT:
Standardization of Uveitis Nomenclature (SUN) Working Group.
Standardization of uveitis nomenclature for reporting clinical
data. Results of the first international workshop. Am J Ophthalmol.
140:509–516. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jabs DA and Busingye J: Approach to the
diagnosis of the uveitides. Am J Ophthalmol. 156:228–236.
2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Trusko B, Thorne J, Jabs D, Belfort R,
Dick A, Gangaputra S, Nussenblatt R, Okada A and Rosenbaum J: The
standardization of uveitis nomenclature (SUN) project. Development
of a clinical evidence base utilizing informatics tools and
techniques. Methods Inf Med. 52:259–265, S1-S6. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Okada AA and Jabs DA: The standardization
of uveitis nomenclature project: The future is here. JAMA
Ophthalmol. 131:787–789. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Samuel MA, Equi RA, Chang TS, Mieler W,
Jampol LM, Hay D and Yannuzzi LA: Idiopathic retinitis, vasculitis,
aneurysms, and neuroretinitis (IRVAN): New observations and a
proposed staging system. Ophthalmology. 114:1526–1529.e1.
2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Atas F, Kayabasi M and Saatci AO: The
place of dexamethasone implant in patients with
Vogt-Koyanagi-Harada disease who experienced systemic
treatment-related hepatic dysfunction: A case series. Taiwan J
Ophthalmol, 2022. DOI: 10.4103/2211-5056.357850. https://journals.lww.com/tjop/Abstract/9000/The_place_of_dexamethasone_implant_in_patients.99978.aspx).
|
|
13
|
Rossetto JD, Nascimento H, Fernandes DD,
Belfort R Jr and Muccioli C: Treatment of cystoid macular edema
secondary to chronic non-infectious intermediate uveitis with an
intraocular dexamethasone implant. Arq Bras Oftalmol. 78:190–193.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bajwa A, Peck T, Reddy AK, Netland PA and
Shildkrot Y: Dexamethasone implantation in birdshot
chorioretinopathy-long-term outcome. Int Med Case Rep J.
11:349–358. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gemperline TP and Smith BT: Treatment of
bilateral diffuse uveal melanocytic proliferation with intravitreal
steroid implants. Retin Cases Brief Rep. 16:461–465.
2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Miserocchi E, Berchicci L, Iuliano L,
Modorati G and Bandello F: Dexamethasone intravitreal implant in
serpiginous choroiditis. Br J Ophthalmol. 101:327–332.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Malclès A, Nguyen AM, Mathis T, Grange JD
and Kodjikian L: Intravitreal dexamethasone implant
(Ozurdex®) for exudative retinal detachment after proton
beam therapy for choroidal melanoma. Eur J Ophthalmol. 27:596–600.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Burkholder BM, Moradi A, Thorne JE and
Dunn JP: The dexamethasone intravitreal implant for noninfectious
uveitis: Practice patterns among uveitis specialists. Ocul Immunol
Inflamm. 23:444–453. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tsang AC, Virgili G, Abtahi M and Gottlieb
CC: Intravitreal dexamethasone implant for the treatment of macular
edema in chronic non-infectious uveitis. Ocul Immunol Inflamm.
25:685–692. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Alba-Linero C, Sala-Puigdollers A, Romero
B, Llorenç V, Adan A and Zarranz-Ventura J: Long-term intravitreal
dexamethasone implant outcomes in uveitis. Ocul Immunol Inflamm.
28:228–237. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mathis T, Cerquaglia A, Weber M,
Guillarme-Sallit R, Malclès A, Voirin N, Servant M, Sudhalkar A,
Bilgic A, Denis P, et al: Uveitis treated with dexamethasone
implant. Retina. 41:620–629. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hasanreisoglu M, Gulpinar Ikiz G, Aktas Z
and Ozdek S: Intravitreal dexamethasone implant as an option for
anti-inflammatory therapy of tuberculosis uveitis. Int Ophthalmol.
39:485–490. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zarranz-Ventura J, Carreño E, Johnston RL,
Mohammed Q, Ross AH, Barker C, Fonollosa A, Artaraz J, Pelegrin L,
Adan A, et al: Multicenter study of intravitreal dexamethasone
implant in noninfectious uveitis: Indications, outcomes, and
reinjection frequency. Am J Ophthalmol. 158:1136–1145.e5.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pohlmann D, Vom Brocke GA, Winterhalter S,
Steurer T, Thees S and Pleyer U: Dexamethasone inserts in
noninfectious uveitis: A single-center experience. Ophthalmology.
125:1088–1099. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zeng S, Yang L, Bai F, Liu T and Liu X:
Intravitreal dexamethasone implant for noninfectious uveitis in
Chinese patients. Int Ophthalmol. 42:2063–2069. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Breitbach M, Rack D, Dietzel M, Heinz C
and Heiligenhaus A: Efficacy of a dexamethasone implant for the
treatment of refractory cystoid macular oedema in non-infectious
uveitis. Klin Monbl Augenheilkd. 233:601–605. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Tufail A, Lightman S, Kamal A, Pleyer U,
Paniagua NMG, Dot C, Li XY, Jiao J, Lou J and Hashad Y: CONSTANCE
Study Group. Post-marketing surveillance study of the safety of
dexamethasone intravitreal implant in patients with retinal vein
occlusion or noninfectious posterior segment uveitis. Clin
Ophthalmol. 12:2519–2534. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Thorne JE, Sugar EA, Holbrook JT, Burke
AE, Altaweel MM, Vitale AT, Acharya NR, Kempen JH and Jabs DA:
Multicenter Uveitis Steroid Treatment Trial Research Group.
Periocular triamcinolone vs intravitreal triamcinolone vs
intravitreal dexamethasone implant for the treatment of uveitic
macular edema: The periocular vs intravitreal corticosteroids for
uveitic macular edema (POINT) trial. Ophthalmology. 126:283–295.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bodaghi B, Brézin AP, Weber M, Delcourt C,
Kodjikian L, Provost A, Velard MÈ, Barnier-Ripet D, Pinchinat S and
Dupont-Benjamin L: Real-life efficacy, safety, and use of
dexamethasone intravitreal implant in posterior segment
inflammation due to non-infectious uveitis (LOUVRE 2 Study).
Ophthalmol Ther. 11:1775–1792. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kang EY, Garg SJ, Chen HF, Wu WC, Chen LY,
Chou HD, Liu L, Chen KJ and Hwang YS: Intravitreal dexamethasone
implants for refractory macular edema in eyes with noninfectious
uveitis. J Clin Med. 10(3762)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Deng J, Sun WT, Ai H and Wang LP:
Combination of cataract surgery with intravitreal injection of
dexamethasone intravitreal implant (Ozurdex) for uveitis-induced
cataract. Int J Ophthalmol. 16:361–366. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Harapriya A and Anthony E: Managing
cataract surgery in patients with uveitis. Community Eye Health.
31:82–83. 2019.PubMed/NCBI
|
|
33
|
Li YT, Cui XX, Yang XT, Li B, Ren XJ, Li
XR and Zhang XM: Utilizing dexamethasone intravitreal implant to
control postoperative inflammation in refractory uveitis undergoing
cataract surgery. Int J Ophthalmol. 14:317–322. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cordero-Coma M, Garzo I, Calleja S, Galán
E, Franco M and Ruíz de Morales JG: Preoperative cataract surgery
use of an intravitreal dexamethasone implant (Ozurdex) in a patient
with juvenile idiopathic arthritis and chronic anterior uveitis. J
AAPOS. 17:632–634. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
da Rocha Lima B, Pichi F, Nucci P,
Srivastava SK and Lowder CY: Fibrin reaction after uveitic cataract
surgery: Treatment and prevention. Eur J Ophthalmol. 24:626–628.
2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chen PL and Chen SN: Efficacy of
intravitreal dexamethasone implant in patients with
Vogt-Koyanagi-Harada disease and bilateral panuveitis: Two case
reports. Medicine (Baltimore). 100(e27394)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Elhamaky TR: Long-term efficacy of
dexamethasone intravitreal implant in the treatment of
Vogt-Koyanagi-Harada disease relapsing posterior uveitis. Indian J
Ophthalmol. 70:2465–2470. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Saatci AO, Ayhan Z, Engin Durmaz C and
Takes O: Simultaneous single dexamethasone implant and ranibizumab
injection in a case with active serpiginous choroiditis and
choroidal neovascular membrane. Case Rep Ophthalmol. 6:408–414.
2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Multicenter Uveitis Steroid Treatment
Trial (MUST) Research Group, Writing Committee. Acharya NR, Vitale
AT, Sugar EA, Holbrook JT, Burke AE, Thorne JE, Altaweel MM, Kempen
JH and Jabs DA: Intravitreal therapy for uveitic macular
edema-ranibizumab versus methotrexate versus the dexamethasone
implant: The MERIT trial results. Ophthalmology: Jun 13, 2023 (Epub
ahead of print).
|
|
40
|
Fonollosa A, Llorenç V, Artaraz J, Jimenez
B, Ruiz-Arruza I, Agirrebengoa K, Cordero-Coma M, Costales-Mier F
and Adan A: Safety and efficacy of intravitreal dexamethasone
implants in the management of macular edema secondary to infectious
uveitis. Retina. 36:1778–1785. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
De Simone L, Sangiovanni A, Aldigeri R,
Mastrofilippo V, Bolletta E, Invernizzi A, Fares L, Pipitone N,
Fontana L, Salvarani C and Cimino L: Interferon alpha-2a treatment
for post-uveitic refractory macular edema. Ocul Immunol Inflamm.
28:322–328. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Khan AA, Kontos G, Paterson-Brown SP and
Dhillon B: Intravitreal dexamethasone implant (ozurdex) to control
recurrent severe idiopathic uveitis leads to improvement in
steroid-induced diabetes mellitus. Ocul Immunol Inflamm.
26:313–314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mantravadi AV and Myers JS: Reconsidering
trabeculectomy's strengths and weaknesses. Clin Exp Ophthalmol.
38:827–828. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Aref AA, Gedde SJ and Budenz DL: Glaucoma
drainage implant surgery. Dev Ophthalmol. 59:43–52. 2017.PubMed/NCBI View Article : Google Scholar
|
